Artificial endonucleases consisting of a FokI cleavage domain tethered to engineered zinc-finger DNA-binding proteins have proven useful for stimulating homologous recombination in a variety of cell types. Because the catalytic domain of zinc-finger nucleases (ZFNs) must dimerize to become active, two subunits are typically assembled as heterodimers at the cleavage site. The use of ZFNs is often associated with significant cytotoxicity, presumably due to cleavage at off-target sites. Here we describe a structure-based approach to reducing off-target cleavage. Using in silico protein modeling and energy calculations, we increased the specificity of target site cleavage by preventing homodimerization and lowering the dimerization energy. Cell-based recombination assays confirmed that the modified ZFNs were as active as the original ZFNs but elicit significantly less genotoxicity. The improved safety profile may facilitate therapeutic application of the ZFN technology.
Targeted gene modification by homologous recombination is a rare event in mammalian cells 1 , which occurs with a frequency of about 1 event per 10 6 cells. The frequency can be greatly increased by introducing a targeted DNA double-strand break near the site of the desired recombination event. Several studies have reported genetargeting frequencies of 1-18% homologous recombination events per mammalian cell when the targeted double-strand break was introduced by natural or artificial endonucleases [2] [3] [4] [5] [6] [7] [8] . This method hence generates precise modifications of the genome in up to one in five mammalian cells and has the potential to be a useful tool for genetic studies, biotechnology and gene therapy.
ZFNs can be engineered to cleave at a user-determined target site. They are composed of the catalytic domain of the restriction enzyme FokI tethered to an engineered zinc-finger DNA-binding protein 9 . A single zinc-finger motif consists of 28 residues and includes an a-helix that contacts three bases in the major groove of DNA. Through modular assembly of such zinc-finger modules, artificial DNA-binding domains can be created to bind to a wide variety of DNA sequences [10] [11] [12] [13] [14] . Hence, a DNA-binding domain consisting of three zinc-finger motifs is expected to bind 9 bp of DNA. Many engineered three-finger proteins have been shown to have excellent binding specificity in vitro, whereas others are less specific [10] [11] [12] [13] [14] [15] .
Because the active ZFN is a dimer, two subunits are typically designed to recognize the target sequence in a tail-to-tail conformation 16, 17 . The C-terminal FokI domains are positioned in close proximity on the same face of the DNA helix by separating the two zinc-finger binding sites by a 6-bp spacer 18 . Thus, the required combination of two ZFN subunits, each containing three fingers, theoretically recognizes an 18-bp site, which defines a unique address in a mammalian genome. A typical application requires two distinct ZFN subunits to bind as a heterodimer at the desired cleavage site. However, symmetry at the FokI dimerization interface also permits homodimers to form, thus enabling cleavage at 9-bp sites recognized by a homodimer. Moreover, at high ZFN concentrations, dimerization may occur in the absence of correct DNA binding, resulting in activation of the nuclease and cleavage at nonintentional sites.
In previous work, we described two ZFNs, GZF1-N and GZF3-N ( Supplementary Fig. 1 online) , which form an active heterodimer and stimulate chromosomal recombination at a frequency of 1% in human embryonic kidney (HEK)293 cells 8 . However, we and others have observed that these and other ZFNs induce considerable cytotoxicity likely arising from cleavage at off-target sites 7, 8 . Such toxicity results, at least, in part from the lack of allosteric regulation, which, in the natural FokI enzyme, keeps the catalytic domains in an inactive conformation in the absence of cognate-DNA binding 17 . Because the enzymatic activity of ZFNs is not regulated in this manner, we investigated the effects of various modifications to the FokI dimerization interface as an approach to reducing ZFN-induced cytotoxicity.
Several computational approaches have shown that novel enzyme specificities can be generated through redesign of dimer interfaces [19] [20] [21] . We used three-dimensional (3D) protein modeling based on the published crystal structures of FokI 22, 23 followed by computational analysis of dimerization to identify residues that affect dimer formation. Subsequent evaluation of mutant ZFNs in cell-based recombination assays verified that modifications, which reduce the dimerization energy and promote heterodimerization, retain their endonuclease activity but elicit substantially reduced toxicity.
RESULTS
We hypothesized that toxicity associated with ZFNs is at least partly due to the absence of regulation of DNA cleavage. Because the FokI nuclease domain is only active as a dimer 16, 17 , altering the dimerization behavior of the two ZFN subunits could improve cleavage specificity.
Protein modeling and in silico mutagenesis
To identify and characterize the critical residues involved in dimerization of ZFNs, we established 3D protein models based on the crystal structure of the native FokI endonuclease 22 . Although the published crystal structures 22, 23 do not provide a clear-cut view of the active enzyme bound to DNA, they offer useful information for structureaided design of point mutations that may alter dimerization of ZFNs (Fig. 1a) .
Structural analysis suggested that dimerization is mainly mediated by helices a4 (residues 479-490) and a5 (residues 528-539) of the cleavage domain 23 . A combination of structural and functional data revealed that D483 may contact R487 in the other subunit (Fig. 1b) through bidentate hydrogen bonds 17, 23 . Our 3D model revealed that an additional contact might exist between Q486 and E490 of the opposing monomer (Fig. 1c) . Furthermore, isoleucines in the interhelical sequence (I499) and in a5 (I538) may stabilize the dimer through hydrophobic interactions (Fig. 1d) . Rational redesign based on this model predicts that an asymmetric dimer interface can be created by swapping a critical pair of interacting residues, like D483R or R487D (Fig. 1e) . In such a case, similarly charged residues, D483/ D487 (DD) or R483/R487 (RR), would be situated in the same subunit, making the formation of homodimers unlikely, owing to electrostatic repulsion. The same rationale applies to the interacting residues Q486 and E490: variants EE (Q486E) and QK (E490K) should favor heterodimerization over homodimerization (Fig. 1f) . Altering the hydrophobic residues I499A or I538V (Fig. 1g,h ) is expected to reduce the dimerization energy without changing the preference for dimer formation. Because of the low protein-protein interaction energy, variants AI (I499A) and IV (I538V) are expected to form only after the monomers bind to the target sequence.
These model-based predictions were supported by calculations based on the computer algorithm FoldX 24 , which permits a quantitative estimation of the stability of protein-protein interactions 25, 26 . Heterodimerization of variants DD with RR and EE with QK is energetically preferred over formation of the respective homodimers (Fig. 1i) . All combinations involving variants AI and IV revealed reduced dimerization activity. The same is true for double mutant D483A/R487A (AA), which has been described as dimerization defective 17 .
In vitro cleavage assays
The in vitro activity and specificity of GZF1-N and GZF3-N homoand heterodimers was analyzed by incubating purified ZFNs with a DNA fragment containing a GZF1-N homodimer site (1-1), a GZF3-N homodimer site (3-3) or a combined GZF3-N/GZF1-N heterodimer target site (3-1) (Fig. 2a) . As predicted by FoldX, the respective homodimer target sequences were cleaved by wild-type GZF1-N or GZF3-N and, to some extent, by variants containing the QK and IV variation (Fig. 2b) . Unexpectedly, variant AI also cleaved at the homodimeric target sequence. All other variations in the dimer interface prevented cleavage at homodimeric targets. For the wild-type and all the variant FokI domains, the heterodimer target (3-1) was cleaved only by the appropriate combination of GZF1-N and GZF3-N, suggesting a high specificity of DNA binding. 
ZFN dimerization variants stimulate SSA
The potential of GZF1-N and GZF3-N to stimulate single-strand annealing (SSA)-based homologous recombination in 293T cells was analyzed using a plasmid-based assay (Fig. 3a) . A luciferase reporter gene was split into two inactive fragments separated by stop codons and a ZFN target site. Introduction of a double-strand break at the ZFN target site initiates SSA between the homologous regions, producing an active luciferase gene. 293T cells were transfected with the indicated SSA reporter plasmids and different ratios of ZFN-expression plasmids.
Increasing the concentration of GZF1-N expression plasmid resulted in increased SSA activation on the 1-1 reporter (Fig. 3b) , whereas GZF3-N failed to similarly stimulate SSA on a 3-3 homodimer reporter. SSA activation by GZF1-N/GZF3-N heterodimers was detectable only at low concentrations of GZF3-N. Homodimers of variants RR, DD, QK and EE failed to stimulate SSA on their corresponding homodimer reporters, suggesting that homodimerization is considerably reduced, whereas variants IV and IA showed moderate to low activity. The dimerizationdefective mutants AA-AA did not induce SSA.
The pair-wise analysis of the individual variants on the 3-1 heterodimer reporter indicated that combinations of variants DD-RR or EE-QK displayed SSA activation (Fig. 3c) , whereas the homologous combinations did not. In contrast, all combinations including variants AI and IV revealed some activity. The potential toxicity of GZF3-N was probed using a 1-1 homodimer reporter. GZF1-N-mediated SSA was rapidly attenuated upon the introduction of wild-type GZF3-N (Fig. 3d) . In contrast, when GZF3-N harboring the IV mutation was used, the expected gradual decrease in SSA was observed.
In conclusion, the SSA results largely confirmed the predictions made by FoldX. Destabilizing dimerization (AI/IV) attenuated activity of the ZFNs, whereas an asymmetric dimer interface (EE/QK and DD/ RR) reduced homodimerization of the ZFN subunits.
ZFN-dimerization variants stimulate gene targeting
The ability of the modified ZFNs to promote homologous recombination was evaluated in a plasmid-based EGFP-rescue assay 8 . The target plasmid (Fig. 4a ) contains a lacZ gene followed by stop codons and a 5¢-truncated EGFP gene (qGFP) 27 . The binding sites for I-SceI, a natural 18-bp cutter that serves as a positive control, and GZF3-N/GZF1-N were placed between lacZ and qGFP. The repair plasmid harbors a 5¢-truncated lacZ-EGFP fusion gene and is designed In the absence of a nuclease only a few cells turned green, representing nonstimulated homologous recombination. Combined expression of the original GZF1-N and GZF3-N (WT-WT) stimulated homologous recombination to a similar extent as that of I-SceI, with some 12% of transfected cells revealing functional correction of the EGFP gene (Fig. 4b) . The combination of variants with an asymmetric dimer interface (DD-RR and EE-QK) worked at least as well as the original ZFNs. On the other hand, combinations harboring the same mutation on both subunits did not considerably activate homologous recombination. The same was true for ZFN mutants KO-KO, which harbor mutations in the catalytic center of the nuclease domain (D450AG) 17 . All combinations involving the isoleucine variants AI and IV stimulated homologous recombination significantly (P o 0.001). Upon expression of the combination IV-AI, 30% of transfected cells underwent homologous recombination, corresponding to a 2.5-fold increase as compared with the wild-type configuration. Evaluation of the expression levels by quantitative immunoblotting showed that the ZFN expression levels were roughly equivalent, with a slight decrease in the steady-state levels for the wildtype ZFNs and the QK variants (Fig. 4c) .
To determine the activity of the modified nucleases in a chromosomal setting, we assessed the frequency of EGFP rescue in cell line 293/3-1, which contains a single integrated copy of the target locus 8 .
The number of EGFP-positive 293/3-1 cells was determined 7 d after transfection with a repair plasmid and the various ZFN combinations (Fig. 4d) . In the absence of a nuclease, o0.1% of cells turned green. As seen previously 4, 8, [28] [29] [30] [31] , expression of I-SceI increased homologous recombination 155-fold, corresponding to 11% of transfected cells undergoing homologous recombination. After transfection by the original ZFN expression vectors (WT-WT), the transfected cells were too low in number (probably because of high toxicity) for the frequency of homologous recombination to be assessed. Combinations including the asymmetric ZFN variants or the isoleucine variants stimulated homologous recombination significantly (P o 0.001) above basal homologous recombination, reaching 1.3% to 3.8%. We did not observe an increase in homologous recombination frequency in the absence of a repair plasmid, or with either the dimerizationdefective (AA-AA) or the catalytic dead mutants (KO-KO). Importantly, the highly significant (P o 0.001) improvements regarding ZFN performance cannot be solely reduced to differences in the ZFN expression levels (Fig. 4c) .
The asymmetric ZFN mutants were then combined with the weakened dimer interface to create double variants (Fig. 5a) , and comparable steady-state expression levels were confirmed by quantitative immunoblotting (Fig. 5b) . To assess the gene-repair kinetics, we increased the amount of transfected ZFN expression vectors and determined the extent of EGFP rescue at days 3 and 7. For combinations DD-RR and IV-AI, a fourfold increase in the amount of transfected DNA translated into a 2.5-fold increase in the frequency of homologous recombination ( Fig. 5c; 4.8% and 9.5%). The corresponding double variant RV-DA performed slightly better (9.7%), almost approaching the level of I-SceI-stimulated homologous recombination (19.3%). No increase was observed for EE-QK and the analogous double variant KV-EA, suggesting that higher amounts of these combinations may be toxic. As a result of the high cytotoxicity associated with the original ZFNs (WT-WT), the homologous recombination frequency was measurable only at day 3 with the lower DNA amount (0.75%). Taken together, these results show that performance of ZFNs can be significantly P o 0.001 (see legend to Figure 5 ) improved by destabilizing dimerization of the two subunits and by promoting heterodimer formation.
Use of ZFN dimerization variants elicits lower toxicity
Several of the preceding experiments suggested that improved ZFN performance is closely linked to reduced toxicity. One of the earliest responses after the creation of a double-strand break is phosphorylation of histone H2AX (g-H2AX) and formation of repair foci near the double-strand break 32, 33 . Consequently, ZFN-associated genotoxicity was determined by quantitatively assessing the level of g-H2AX in response to expression of the ZFNs in transfected HT1080 cells (Fig. 6) . The assay was validated by incubating the cells with etoposide, a known inducer of double-strand breaks 34 . As determined by flow cytometry and immunofluorescence, increasing the concentration of etoposide led to elevated levels of g-H2AX in the cells (Fig. 6a) as well as the formation of g-H2AX containing repair foci (Fig. 6d) .
As compared with the catalytic dead mutants (KO-KO), expression of the original ZFNs (WT-WT) significantly increased the overall level of g-H2AX (Fig. 6b) , the number of highly g-H2AX-positive cells (Fig. 6c ) and the number of repair foci (Fig. 6d) . On the other hand, combinations involving the asymmetric DD-RR or the weak IV-AI dimer interface revealed a substantially reduced genotoxicity. In good agreement with the chromosomal gene repair data, QK-EE was more toxic than the other variants and the lowest toxicity was measured for the double variant RV-DA. Taken together with the previous experiments, these assays confirm that targeted modifications to the FokI dimerization interface substantially reduce toxicity induced by ZFNs and, in doing so, enhance their performance.
DISCUSSION
This report demonstrates that specific mutations within the dimer interface of ZFNs attenuate their toxicity while promoting robust homologous recombination. ZFN-induced toxicity most likely results from cleavage at off-target sites, which is determined by multiple factors, including the specificity of DNA binding and DNA cleavage. We hypothesized that targeted changes to the dimer interface of ZFNs would reduce toxicity associated with off-target cleavage. Using 3D protein modeling and computer-based energy calculations, we identified potential residues in the FokI dimer interface that are involved in dimerization of ZFNs. Two general strategies were pursued. The exchange of interacting charged residues in the protein-protein interface created asymmetric dimerization variants that contained similarly charged residues in the same subunit. In the chromosomal homologous recombination assay, variant DD-RR performed better than EE-QK, probably because at high ZFN concentrations EE-EE homodimers could also form, which might contribute to the observed toxicity. This is in agreement with the computer analysis predicting that DD-DD and RR-RR homodimers are much less favored than EE-EE and QK-QK homodimers. The isoleucine variants IV-AI, which are expected to dimerize only after binding to the respective target site, also performed well. The combination of both strategies proved especially effective. Probably owing to its low genotoxicity, the variant combining DD/RR with IV/AI stimulated homologous recombination almost as well as the gold standard I-SceI. A scan of the human genome revealed 28,104 binding sites for GZF1, 12,647 GZF3 sites, a single heterodimeric GZF3-GZF1 site (the inserted target locus) and no binding sites for the homodimers GZF1-GZF1 and GZF3-GZF3 (data not shown). This suggests that the effective ZFN concentration rather than cleavage at homodimeric sites seems to determine toxicity. The actual mechanism by which the variants overcome toxicity is speculative and complicated by a lack of knowledge of many key details. The natural FokI restriction enzyme binds DNA as a monomer. To cleave DNA, two monomers associate through their catalytic domain to form a dimer with two active sites. In vitro studies showed that an active FokI dimer can also form with just one subunit being bound to its recognition site 35 . We speculate that ZFNs may work the same way. At high concentrations, a dimeric ZFN complex with just one monomer attached to DNA could form and contribute to toxicity. By destabilizing the dimer interface, as in the case of the isoleucine variants, these off-target effects would be lost, because the interaction energy for these complexes to form is too low. Variants that create an asymmetric dimerization interface may work in a related way. Preventing the formation of homodimers lowers the number of possible interaction partners and hence the number of active ZFNs.
Two studies apparently identified nontoxic ZFNs that contained a wild-type FokI interface 2, 36 . These ZFNs were possibly composed of zinc-finger domains that had better DNA-binding specificity than those used in this study. Depending on the specificity of the zincfinger DNA-binding domain, the dimeric ZFN complex may recognize a more or a less closely related family of 18-bp target sequences, which suggests that an active complex can also form if one or both monomers bind at appropriately spaced pseudo-sites at reduced affinity. Higher specificity of DNA-binding consequently means that fewer ZFN monomers are bound to pseudosites, which translates into fewer cleavage events. Characterizing the in vitro and cell-based affinity and specificity of the reported ZFNs would help to address this issue.
In summary, our results present both forced heterodimerization and destabilized interaction between two monomers as successful methods that can be combined to substantially reduce ZFN-associated toxicity while retaining activity. These findings should be useful in developing the ZFN technology for the study of gene function and for therapeutic applications.
METHODS
FoldX-based mutagenesis. Mutagenesis modeling and energy calculations were done with FoldX version 2.65 (http://foldx.embl.de), as previously described 24, 26, [37] [38] [39] . In this FoldX version we ensured that the same neighbors, which are moved in the mutant, are also moved in the wild-type protein. Thus, for each mutant a specific reference wild-type protein is generated, which results in a considerable improvement in the prediction of mutation effects (F. Stricher, J. Schymkowitz, J. Borg and L. Serrano, personal communication). Overall stability of the dimer as well as the binding energy was determined. In this way we ensured that our mutations were mainly affecting dimer formation and not monomer stability. Details are described in previous publications 24, 37, 40 .
Plasmids. Target plasmid pCMV.LacZs31qGFP, repair plasmids pUC.Zgfp/Rex and pUC.Zgfp, and the nuclease expression vectors pRK5.LHA-Sce1, pRK5.GZF1-N, pRK5.GZF3-N, pPGK.GZF1-N and pPGK.GZF3-N have been described before 8 . Point mutations were introduced into the ZFN expression plasmids using site-directed mutagenesis. SSA reporter plasmids were generated in a pGL3 vector (Promega) background. PCR was used to amplify a 5¢-and a 3¢-fragment of the luciferase gene, each containing an 870-bp region of homologous overlap. The 5¢-and 3¢-fragments were inactive owing to the respective truncations at the opposite ends. They were cloned into pGL3 using the introduced EcoRI site to join the fragments. The ZFN target sites are contained in the junction of the fragments (Fig. 3a) . To generate bacterial expression vectors, we amplified GZF1-N and GZF3-N by PCR and subcloned them into pMal2-c2X (New England Biolabs), which appends an N-terminal maltose-binding protein (MBP) domain for purification. Detailed maps and sequence files of the plasmids can be obtained upon request.
MBP-ZFN purification and in vitro assay. MBP-ZFN fusion proteins were expressed in E. coli strain ER2508 (New England Biolabs). Expression of ZFNs was induced for 2 h with IPTG (0.3 mM) in the presence of ZnCl 2 (0.1 mM). The cells were subsequently lysed and sonicated in lysis buffer (50 mM Tris-HCl (pH 8.0), 20 mM KCl, 2 mM MgCl 2 , 1 mM DTT, 0.2% Triton X-100 and complete protease inhibitor without EDTA (Roche)). Protein purification using amylose resin (New England Biolabs) and elution in lysis buffer containing 10 mM maltose was performed as recommended by the manufacturer. Proteins were stored in 30% glycerol at -20 1C until use. ZFN activities were analyzed in cleavage buffer (10 mM Tris-HCl (pH 8.0), 90 mM KCl, 0.1 mM ZnCl 2 , 5 mM DTT) using 0.5 mg (100 fmol) of a linear DNA substrate corresponding to the SSA reporter plasmids (cleaved at XhoI) and 50 ng (500 fmol) of each purified protein. The reactions were incubated for 15 min at 25 1C before adding MgCl 2 to 10 mM, followed by an additional incubation of 30 min at 37 1C and analysis on a 1% agarose gel. to analyze activity. After 24 h, the cells were lysed in1Â lysis buffer (Promega) and luciferase activity was determined using BrightGlo (Promega) in a plate luminometer (Molecular Devices). For the episomal homologous recombination assay, 293T cells in 24-well plates were transfected by calcium phosphate precipitation with 20 ng of a target plasmid, 1 mg of the repair plasmid (pUC.Zgfp/REx) or a repair control (pUC.REx), and 0.5 mg of a PGK-driven endonuclease expression vector encoding the ZFNs, I-SceI (pRK5.LHA-Sce1) or a control vector (pCMV.Luc). Two days after transfection, 50,000 cells were analyzed by flow cytometry (FACSCalibur, BD Bioscience) to determine the percentage of EGFP-and REx-positive cells. For the chromosomal homologous recombination assay, 293/3-1 cells in 12-well plates were transfected by calcium phosphate precipitation with 2 mg of the repair plasmid (pUC.Zgfp) or a repair control (pUC118), 100 or 400 ng of a cytomegalovirus (CMV)-driven nuclease expression vector or control vector (pCMV.Luc), and 10 ng of pDsRed-Express-N1 (Clontech). We analyzed 50,000 cells by flow cytometry 3 and 7 d after transfection to determine the percentage of EGFPand REx-positive cells. The number of REx-positive cells at day 3 was used to normalize for transfection efficiency. If the percentage of transfected cells at day 3 dropped below 1%, results were not evaluated.
Quantitative immunoblotting. 293T cells in 35-mm wells were transfected by calcium phosphate precipitation with 800 ng of a CMV-controlled ZFN expression plasmid, 200 ng of pEGFP (Clontech) and pUC118 to 4 mg. After 30 h cells were harvested and resuspended in lysis buffer 8 . Equal amounts of proteins (50 mg) were separated by SDS PAGE and transferred to Immobilon-P membrane (Millipore). The blots were concomitantly incubated with a rabbit anti-HA antibody (Novus Biologicals, 1:5,000) and with mouse anti-GFP antibody MAB3580 (Chemicon, 1:5,000) for 2 h at 25 1C. After incubation with secondary antibodies conjugated with IRDye-680 or IRDye-800CW (Li-Cor Bioscience, both 1:20,000), protein expression was visualized and quantified using an Odyssey scanner (Li-Cor Bioscience) according to the manufacturer's instructions.
Indirect immunofluorescence.
Immunofluorescence was basically performed as described 41, 42 . Briefly, HT1080 cells on gelatin-coated 13-mm glass cover slips were transfected with 200 ng each of a CMV-controlled ZFN expression plasmid and pUC118 to 800 ng using Lipofectamine 2000 (Invitrogen). Alternatively, cells were exposed to etoposide at the indicated concentrations for 60 min 2 h before harvesting. After 30 h, cells were fixed with 4% paraformaldehyde in PBS and permeabilized in 0.5% Triton X-100. After blocking, cells were incubated for 1 h with mouse anti-gH2AX (Upstate no. 05-636; 1:1,000) and rabbit anti-HA (Novus Biologicals no. NB600-363; 1:2,000) in 3% BSA in PBS, followed by staining for 1 h with Cy2-conjugated goat anti-mouse, Cy3-conjugated goat anti-rabbit (both Jackson ImmunoResearch; 1:500) and 1 mg/ml 4,6-diamidino-2-phenyindole (DAPI; Sigma) in 1% BSA in PBS. Cover slips were mounted with Fluoromount-G (Southern Biotechnology) and analyzed by fluorescence microscopy.
Quantitative genotoxicity assay. HT1080 cells in 12-well plates were transfected with 400 ng each of a CMV-controlled nuclease expression vector, 400 ng of pEGFP-tubulin 8 , and pUC118 to 1.6 mg using Lipofectamine 2000. Alternatively, cells were exposed to etoposide at the indicated concentrations for 60 min 2 h before harvesting. Cells were collected after 30 h by trypsinization and fixed in 75% ethanol. After blocking in 3% BSA in PBS, cells were stained for 2 h at 4 1C with mouse anti-gH2AX (Upstate; 1:1,000) in 3% BSA, followed by incubation for 1 h at 4 1C with AlexaFluor594-conjugated goat anti-mouse (Molecular Probes; 1:200) in 1% BSA in PBS. 25,000 cells were analyzed by flow cytometry (FACSCalibur) to determine the level of gH2AX in EGFP-positive cells.
Statistical analysis. For all assays, statistical significance was determined using a two-sided student's t-test with unequal variance.
Request for reagents. Requests for reagents relating to the SSA or the in vitro assays should be addressed to D.J.S. For all other requests contact T.C.
